Exact Mass: 345.1141

Exact Mass Matches: 345.1141

Found 119 metabolites which its exact mass value is equals to given mass value 345.1141, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Omeprazole

6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-methyl-1H-benzo[d]imidazole

C17H19N3O3S (345.1147)


Omeprazole is a highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers, dyspepsia, peptic ulcer disease , gastroesophageal reflux disease and Zollinger-Ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of Gastric Parietal Cells.--Pubchem. Omeprazole is one of the most widely prescribed drugs internationally and is available over the counter in some countries. Proton pump inhibitor, inhibits gastric acid secretion. Antiulcer agent. It is used in combination with Amoxicillin for eradication of Helicobacter pylori and for the treatment of gastroesophageal reflux disease (CCD) A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

   

Candimine

Candimine

C18H19NO6 (345.1212)


A natural product found in Hippeastrum morelianum and Hippeastrum candidum.

   

Isofenphos

2-[[Ethoxy[(1-methylethyl)amino]phosphinothioyl]oxy]benzoic acid 1-methylethyl ester

C15H24NO4PS (345.1164)


Isofenphos is an Agricultural insecticide with contact and stomach actio C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals

   

2-descarboxy-betanidin

2-descarboxy-betanidin

C17H17N2O6+ (345.1087)


   

Esomeprazole

5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl]-1H-1,3-benzodiazole

C17H19N3O3S (345.1147)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor

   

Esomeprazole

5-methoxy-2-[(S)-(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole

C17H19N3O3S (345.1147)


Esomeprazole is a proton pump inhibitor (brand names Nexium; Esomeprazole is a proton pump inhibitor which reduces gastric acid secretion through inhibition of H+/K+-ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents formation of gastric acid.; Esopral and Axagon in Italy) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below).; Esopral and Axagon in Italy) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below).; Esomeprazole is a proton pump inhibitor (brand names Nexium; Esomeprazole is a proton pump inhibitor (brand names Nexium; Lucen; Esopral and Axagon in Italy) used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole (see below).; Lucen; A highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits the H(+)-K(+)-ATPase (H(+)-K(+)-exchanging ATPase) in the proton pump of gastric parietal cells. [HMDB] Esomeprazole (brand names Nexium; Lucen; Esopral and Axagon in Italy) is a proton pump inhibitor which reduces gastric acid secretion through the inhibition of H+/K+-ATPase in gastric parietal cells. By inhibiting the functioning of this enzyme, the drug prevents the formation of gastric acid. Esomeprazole is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD), and Zollinger-Ellison syndrome. Esomeprazole is the S-enantiomer of omeprazole (marketed as Losec/Prilosec), and AstraZeneca claims improved efficacy of this single enantiomer product over the racemic mixture of omeprazole. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors

   

3-(3-Amino-3-carboxypropyl)uridine

(2S)-2-amino-4-{3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-1-yl}butanoic acid

C13H19N3O8 (345.1172)


   

1-(4-Chlorophenyl)-2-acetyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline

1-[1-(4-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one

C19H20ClNO3 (345.1132)


   

5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

N-(3,4-dimethyl-1,2-oxazol-5-yl)-5-(dimethylamino)naphthalene-1-sulfonamide

C17H19N3O3S (345.1147)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003619 - Dansyl Compounds D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents BMS 182874 is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research[1].

   

4-[2-(3,4-Dihydro-6,7-dimethoxy-4-methyl-3-oxo-2-quinoxalinyl)ethyl]-3H-1,2,4-triazole-3,5(4H)-dione

4-[2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalin-2-yl)ethyl]-4,5-dihydro-3H-1,2,4-triazole-3,5-dione

C15H15N5O5 (345.1073)


   

Oxo-ciprofloxacin

6-fluoro-4-oxo-1-(2-oxocyclopropyl)-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid

C17H16FN3O4 (345.1125)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones

   

Oxociprofloxacin

1-Cyclopropyl-6-fluoro-7-(5-hydroxy-1,2,3,6-tetrahydropyrazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate

C17H16FN3O4 (345.1125)


   

(+)-3-O-Acetylisopteleflorine

(+)-3-O-Acetylisopteleflorine

C18H19NO6 (345.1212)


   

Tecleaverdine

Tecleaverdine

C18H19NO6 (345.1212)


   

Physarorubinic acid A

Physarorubinic acid A

C18H19NO6 (345.1212)


   

3-(3-Amino-3-carboxypropyl)-uridin|3-(3-amino-3-carboxypropyl)uridine|acp3U|X-Nucleosid

3-(3-Amino-3-carboxypropyl)-uridin|3-(3-amino-3-carboxypropyl)uridine|acp3U|X-Nucleosid

C13H19N3O8 (345.1172)


   

(+/-)-N-formyl-1,2-dihydrorenierone|(2-formyl-1,2,5,8-tetrahydro-7-methoxy-6-methyl-5,8-dioxo-1-isoquinolinyl)methyl (2Z)-2-methyl-2-butenoate|N-Formyl-1,2-dihydrorenierone

(+/-)-N-formyl-1,2-dihydrorenierone|(2-formyl-1,2,5,8-tetrahydro-7-methoxy-6-methyl-5,8-dioxo-1-isoquinolinyl)methyl (2Z)-2-methyl-2-butenoate|N-Formyl-1,2-dihydrorenierone

C18H19NO6 (345.1212)


   

(+)-3alpha-hydroxy-6beta-acetylbulbispermine

(+)-3alpha-hydroxy-6beta-acetylbulbispermine

C18H19NO6 (345.1212)


   

1-Hydroxy-2,3,5,6-tetramethoxy-10-methylacridin-9(10H)-one

1-Hydroxy-2,3,5,6-tetramethoxy-10-methylacridin-9(10H)-one

C18H19NO6 (345.1212)


   

Euxylophoricine B

Euxylophoricine B

C20H15N3O3 (345.1113)


   
   

Izumiphenazine C

Izumiphenazine C

C20H15N3O3 (345.1113)


A natural product found in Streptomyces species.

   
   

3, 3鈥樎?Dihydro-Violacein

3, 3鈥樎?Dihydro-Violacein

C20H15N3O3 (345.1113)


   
   
   
   
   
   
   
   

4-Pyridoxic acid O-hexoside

4-Pyridoxic acid O-hexoside

C14H19NO9 (345.106)


   

omeprazole

6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1-methyl-1H-benzo[d]imidazole

C17H19N3O3S (345.1147)


A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 8334 CONFIDENCE standard compound; INTERNAL_ID 1113 Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

   
   

Omeprazole; AIF; CE0; CorrDec

Omeprazole; AIF; CE0; CorrDec

C17H19N3O3S (345.1147)


   

Omeprazole; AIF; CE10; CorrDec

Omeprazole; AIF; CE10; CorrDec

C17H19N3O3S (345.1147)


   

Omeprazole; AIF; CE30; CorrDec

Omeprazole; AIF; CE30; CorrDec

C17H19N3O3S (345.1147)


   

Omeprazole; AIF; CE0; MS2Dec

Omeprazole; AIF; CE0; MS2Dec

C17H19N3O3S (345.1147)


   

Omeprazole; AIF; CE10; MS2Dec

Omeprazole; AIF; CE10; MS2Dec

C17H19N3O3S (345.1147)


   

Omeprazole; AIF; CE30; MS2Dec

Omeprazole; AIF; CE30; MS2Dec

C17H19N3O3S (345.1147)


   

Omeprazole; LC-tDDA; CE10

Omeprazole; LC-tDDA; CE10

C17H19N3O3S (345.1147)


   

Omeprazole; LC-tDDA; CE20

Omeprazole; LC-tDDA; CE20

C17H19N3O3S (345.1147)


   

Omeprazole; LC-tDDA; CE30

Omeprazole; LC-tDDA; CE30

C17H19N3O3S (345.1147)


   

Omeprazole; LC-tDDA; CE40

Omeprazole; LC-tDDA; CE40

C17H19N3O3S (345.1147)


   
   
   
   
   
   
   
   
   

2-amino-6-(4-methoxyphenyl)-3-nitro-4-phenylbenzonitrile

2-amino-6-(4-methoxyphenyl)-3-nitro-4-phenylbenzonitrile

C20H15N3O3 (345.1113)


   

N-tert-butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide

N-tert-butyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)thiophene-2-sulfonamide

C14H24BNO4S2 (345.124)


   

R-Fluoxetine hydrochloride

(R)-Fluoxetine Hydrochloride

C17H19ClF3NO (345.1107)


C78272 - Agent Affecting Nervous System > C94725 - Selective Serotonin Reuptake Inhibitor C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent

   

2-amino-4-(4-methoxyphenyl)-3-nitro-6-phenylbenzonitrile

2-amino-4-(4-methoxyphenyl)-3-nitro-6-phenylbenzonitrile

C20H15N3O3 (345.1113)


   

2-CHLORO-1-(6,7-DIMETHOXY-1-PHENYL-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHANONE

2-CHLORO-1-(6,7-DIMETHOXY-1-PHENYL-3,4-DIHYDRO-1H-ISOQUINOLIN-2-YL)-ETHANONE

C19H20ClNO3 (345.1132)


   

(S)-N1-(2-aminoethyl)-3-(4-ethoxyphenyl)propane-1,2-diamine.3HCl

(S)-N1-(2-aminoethyl)-3-(4-ethoxyphenyl)propane-1,2-diamine.3HCl

C13H26Cl3N3O (345.1141)


   

3-[2-(1H-benzimidazol-2-ylsulfinylmethyl)-3-methylpyridin-4-yl]oxypropan-1-ol

3-[2-(1H-benzimidazol-2-ylsulfinylmethyl)-3-methylpyridin-4-yl]oxypropan-1-ol

C17H19N3O3S (345.1147)


   
   

N-(4-(5-(FURAN-2-YL)-1,3,4-OXADIAZOL-2-YL)PHENYL)-2-PHENYLACETAMIDE

N-(4-(5-(FURAN-2-YL)-1,3,4-OXADIAZOL-2-YL)PHENYL)-2-PHENYLACETAMIDE

C20H15N3O3 (345.1113)


   

Fluoxetine Hydrochloride

Fluoxetine Hydrochloride

C17H19ClF3NO (345.1107)


D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065690 - Cytochrome P-450 CYP2D6 Inhibitors D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017367 - Selective Serotonin Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C94725 - Selective Serotonin Reuptake Inhibitor D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators

   

2-amino-4-(3-methoxyphenyl)-3-nitro-6-phenylbenzonitrile

2-amino-4-(3-methoxyphenyl)-3-nitro-6-phenylbenzonitrile

C20H15N3O3 (345.1113)


   

(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid

(5,6-Diphenyl-furo[2,3-d]pyrimidin-4-ylamino)-acetic acid

C20H15N3O3 (345.1113)


   

(+)-(S)-Fluoxetine Hydrochloride

(+)-(S)-Fluoxetine Hydrochloride

C17H19ClF3NO (345.1107)


   

4-amino-N-[3-(3H-1,3-benzoxazol-2-ylidene)-4-oxo-1-cyclohexa-1,5-dienyl]benzamide

4-amino-N-[3-(3H-1,3-benzoxazol-2-ylidene)-4-oxo-1-cyclohexa-1,5-dienyl]benzamide

C20H15N3O3 (345.1113)


   

2-[[3-(5-Methyl-2-furanyl)-1-oxopropyl]amino]benzene-1,4-dicarboxylic acid dimethyl ester

2-[[3-(5-Methyl-2-furanyl)-1-oxopropyl]amino]benzene-1,4-dicarboxylic acid dimethyl ester

C18H19NO6 (345.1212)


   

2-[[4-(4-Methoxyphenyl)-2-pyrimidinyl]thio]-1-(4-morpholinyl)ethanone

2-[[4-(4-Methoxyphenyl)-2-pyrimidinyl]thio]-1-(4-morpholinyl)ethanone

C17H19N3O3S (345.1147)


   
   

N-[[3-Fluoro-4-ethoxy-pyrid-2-YL]ethyl]-N-[5-nitrilomethyl-pyridyl]-thiourea

N-[[3-Fluoro-4-ethoxy-pyrid-2-YL]ethyl]-N-[5-nitrilomethyl-pyridyl]-thiourea

C16H16FN5OS (345.106)


   

[6-Amino-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium

[6-Amino-9-(2-methoxycarbonylphenyl)xanthen-3-ylidene]azanium

C21H17N2O3+ (345.1239)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D012235 - Rhodamines D004396 - Coloring Agents > D005456 - Fluorescent Dyes

   

Oxociprofloxacin

Oxociprofloxacin

C17H16FN3O4 (345.1125)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D024841 - Fluoroquinolones

   

4-Hydroxy-6-{[(3-methylbutanoyl)oxy](phenyl)methyl}-2-oxo-1,2-dihydropyridine-3-carboxylic acid

4-Hydroxy-6-{[(3-methylbutanoyl)oxy](phenyl)methyl}-2-oxo-1,2-dihydropyridine-3-carboxylic acid

C18H19NO6 (345.1212)


   

4,5-Dimethoxy-2-[(2-phenoxypropanoyl)amino]benzoic acid

4,5-Dimethoxy-2-[(2-phenoxypropanoyl)amino]benzoic acid

C18H19NO6 (345.1212)


   

{[5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-methyl-furan-3-carbonyl]-amino}-acetic acid ethyl ester

{[5-(2,3-Dihydro-benzo[1,4]dioxin-6-yl)-2-methyl-furan-3-carbonyl]-amino}-acetic acid ethyl ester

C18H19NO6 (345.1212)


   

3,4,5-Trimethoxybenzoic acid [(3,5-dimethyl-4-oxo-1-cyclohexa-2,5-dienylidene)amino] ester

3,4,5-Trimethoxybenzoic acid [(3,5-dimethyl-4-oxo-1-cyclohexa-2,5-dienylidene)amino] ester

C18H19NO6 (345.1212)


   

[2-(furan-2-ylmethylamino)-2-oxoethyl] (E)-3-(3,4-dimethoxyphenyl)prop-2-enoate

[2-(furan-2-ylmethylamino)-2-oxoethyl] (E)-3-(3,4-dimethoxyphenyl)prop-2-enoate

C18H19NO6 (345.1212)


   

1-[1-(3-Fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(1-methyl-5-tetrazolyl)thio]ethanone

1-[1-(3-Fluorophenyl)-2,5-dimethyl-3-pyrrolyl]-2-[(1-methyl-5-tetrazolyl)thio]ethanone

C16H16FN5OS (345.106)


   

(4Z)-2-(4-methylphenyl)-4-[(1,2,4-triazol-4-ylamino)methylidene]isoquinoline-1,3-dione

(4Z)-2-(4-methylphenyl)-4-[(1,2,4-triazol-4-ylamino)methylidene]isoquinoline-1,3-dione

C19H15N5O2 (345.1226)


   

N-(1,3-benzodioxol-5-yl)-4-(2-furanylmethyl)-1-piperazinecarbothioamide

N-(1,3-benzodioxol-5-yl)-4-(2-furanylmethyl)-1-piperazinecarbothioamide

C17H19N3O3S (345.1147)


   

N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine

N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine

C20H15N3O3 (345.1113)


   

3-hydroxy-2-(4-methylphenyl)-4-[(E)-1H-1,2,4-triazol-5-yliminomethyl]isoquinolin-1-one

3-hydroxy-2-(4-methylphenyl)-4-[(E)-1H-1,2,4-triazol-5-yliminomethyl]isoquinolin-1-one

C19H15N5O2 (345.1226)


   
   
   
   
   
   
   
   
   
   

UNII:0514MAW53A

UNII:0514MAW53A

C15H24NO4PS (345.1164)


C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D010575 - Pesticides > D007306 - Insecticides D016573 - Agrochemicals

   

5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

5-(Dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide

C17H19N3O3S (345.1147)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003619 - Dansyl Compounds D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents BMS 182874 is an orallyactive, highly selective endothelin receptor (ETA receptor) antagonist, with IC50 value of 0.150 μM, Ki of 0.055 μM. BMS 182874 reduces the arterial pressure of Deoxycorticosterone acetate (HY-B1472) induced hypertension model in rats, and can be used for cardiovascular disease research[1].

   

3-(3-Amino-3-carboxypropyl)uridine

3-(3-Amino-3-carboxypropyl)uridine

C13H19N3O8 (345.1172)


   

SPF-32629B

SPF-32629B

C18H19NO6 (345.1212)


A carboxylic ester obtained by the formal condensation of the benzylic hydroxy group of 4-hydroxy-6-[hydroxy(phenyl)methyl]-2-oxo-1,2-dihydropyridine-3-carboxylic acid with 3-methylbutanoic acid. It is isolated from the culture broth of Penicillium sp. SPF-32629 and acts as an inhibitor of the enzyme chymase (EC 3.4.21.39).

   

Aminocarboxypropyluridine

Aminocarboxypropyluridine

C13H19N3O8 (345.1172)


   

1-hydroxy-2,3,5,6-tetramethoxy-10-methylacridin-9-one

1-hydroxy-2,3,5,6-tetramethoxy-10-methylacridin-9-one

C18H19NO6 (345.1212)


   

3'-o-acetylisopteleflorine

NA

C18H19NO6 (345.1212)


{"Ingredient_id": "HBIN009028","Ingredient_name": "3'-o-acetylisopteleflorine","Alias": "NA","Ingredient_formula": "C18H19NO6","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "442","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

5,10b- epoxy- phenanthridine

NA

C18H19NO6 (345.1212)


{"Ingredient_id": "HBIN010945","Ingredient_name": "5,10b- epoxy- phenanthridine","Alias": "NA","Ingredient_formula": "C18H19NO6","Ingredient_Smile": "COC1CC2C3(C4C1O4)C(=O)CN2CC5=C(C6=C(C=C35)OCO6)OC","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42862","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2-[(13r)-10-methoxy-3,5,14-trioxa-16-azatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1,6,8,10,15-pentaen-13-yl]propan-2-yl acetate

2-[(13r)-10-methoxy-3,5,14-trioxa-16-azatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1,6,8,10,15-pentaen-13-yl]propan-2-yl acetate

C18H19NO6 (345.1212)


   

2-{10-methoxy-3,5,14-trioxa-16-azatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1,6,8,10,15-pentaen-13-yl}propan-2-yl acetate

2-{10-methoxy-3,5,14-trioxa-16-azatetracyclo[7.7.0.0²,⁶.0¹¹,¹⁵]hexadeca-1,6,8,10,15-pentaen-13-yl}propan-2-yl acetate

C18H19NO6 (345.1212)


   

3-(2,3-dimethoxy-5-methylphenyl)-7-methoxyisoindole-1,3,5-triol

3-(2,3-dimethoxy-5-methylphenyl)-7-methoxyisoindole-1,3,5-triol

C18H19NO6 (345.1212)


   

(2e,6e)-2,6-dimethyl-8-(1,4,6-trihydroxy-3-oxoisoindol-5-yl)octa-2,6-dienoic acid

(2e,6e)-2,6-dimethyl-8-(1,4,6-trihydroxy-3-oxoisoindol-5-yl)octa-2,6-dienoic acid

C18H19NO6 (345.1212)


   

5-acetyl-1-[(6,8-dihydroxy-4-methyl-3-methylidene-1-oxo-4h-2-benzopyran-5-yl)methyl]pyrrolidin-2-one

5-acetyl-1-[(6,8-dihydroxy-4-methyl-3-methylidene-1-oxo-4h-2-benzopyran-5-yl)methyl]pyrrolidin-2-one

C18H19NO6 (345.1212)


   

2,6-dimethyl-8-(1,4,6-trihydroxy-3-oxoisoindol-5-yl)octa-2,6-dienoic acid

2,6-dimethyl-8-(1,4,6-trihydroxy-3-oxoisoindol-5-yl)octa-2,6-dienoic acid

C18H19NO6 (345.1212)


   

(2r)-6-[(2e,4e)-5-(3-chloro-1h-pyrrol-2-yl)penta-2,4-dien-2-yl]-2,3,3-trimethyl-2h-furo[3,2-c]pyran-4-one

(2r)-6-[(2e,4e)-5-(3-chloro-1h-pyrrol-2-yl)penta-2,4-dien-2-yl]-2,3,3-trimethyl-2h-furo[3,2-c]pyran-4-one

C19H20ClNO3 (345.1132)


   

6-[(2e,4e)-5-(3-chloro-1h-pyrrol-2-yl)penta-2,4-dien-2-yl]-2,3,3-trimethyl-2h-furo[3,2-c]pyran-4-one

6-[(2e,4e)-5-(3-chloro-1h-pyrrol-2-yl)penta-2,4-dien-2-yl]-2,3,3-trimethyl-2h-furo[3,2-c]pyran-4-one

C19H20ClNO3 (345.1132)


   

(3r)-3-(2,6-dimethoxyphenyl)-6-(hydroxymethyl)-7-methoxy-3h-isoindole-1,4-diol

(3r)-3-(2,6-dimethoxyphenyl)-6-(hydroxymethyl)-7-methoxy-3h-isoindole-1,4-diol

C18H19NO6 (345.1212)


   

1,2,3,5,6-pentamethoxy-10h-acridin-9-one

1,2,3,5,6-pentamethoxy-10h-acridin-9-one

C18H19NO6 (345.1212)


   

1-hydroxy-2,3,6,7-tetramethoxy-10-methylacridin-9-one

1-hydroxy-2,3,6,7-tetramethoxy-10-methylacridin-9-one

C18H19NO6 (345.1212)


   

12-hydroxy-12-[5-(hydroxymethyl)-1-methyl-2,4-dioxopyrrolidin-3-ylidene]dodeca-2,4,6,8,10-pentaenoic acid

12-hydroxy-12-[5-(hydroxymethyl)-1-methyl-2,4-dioxopyrrolidin-3-ylidene]dodeca-2,4,6,8,10-pentaenoic acid

C18H19NO6 (345.1212)


   

9-hydroxy-14-methoxy-4-methyl-11,16,18-trioxa-4-azapentacyclo[11.7.0.0²,¹⁰.0³,⁷.0¹⁵,¹⁹]icosa-1(13),7,14,19-tetraen-12-one

9-hydroxy-14-methoxy-4-methyl-11,16,18-trioxa-4-azapentacyclo[11.7.0.0²,¹⁰.0³,⁷.0¹⁵,¹⁹]icosa-1(13),7,14,19-tetraen-12-one

C18H19NO6 (345.1212)


   

n-{4-methoxy-11'-oxo-4',6',12'-trioxaspiro[cyclohexane-1,10'-tricyclo[7.4.0.0³,⁷]tridecane]-1',2,3'(7'),8'-tetraen-6-yl}-n-methylformamide

n-{4-methoxy-11'-oxo-4',6',12'-trioxaspiro[cyclohexane-1,10'-tricyclo[7.4.0.0³,⁷]tridecane]-1',2,3'(7'),8'-tetraen-6-yl}-n-methylformamide

C18H19NO6 (345.1212)


   

(3s)-3-(2,6-dimethoxyphenyl)-6-(hydroxymethyl)-7-methoxy-3h-isoindole-1,4-diol

(3s)-3-(2,6-dimethoxyphenyl)-6-(hydroxymethyl)-7-methoxy-3h-isoindole-1,4-diol

C18H19NO6 (345.1212)


   

6-[5-(3-chloro-1h-pyrrol-2-yl)penta-2,4-dien-2-yl]-2,3,3-trimethyl-2h-furo[3,2-c]pyran-4-one

6-[5-(3-chloro-1h-pyrrol-2-yl)penta-2,4-dien-2-yl]-2,3,3-trimethyl-2h-furo[3,2-c]pyran-4-one

C19H20ClNO3 (345.1132)


   

(5r)-5-acetyl-1-{[(4s)-6,8-dihydroxy-4-methyl-3-methylidene-1-oxo-4h-2-benzopyran-5-yl]methyl}pyrrolidin-2-one

(5r)-5-acetyl-1-{[(4s)-6,8-dihydroxy-4-methyl-3-methylidene-1-oxo-4h-2-benzopyran-5-yl]methyl}pyrrolidin-2-one

C18H19NO6 (345.1212)


   

(2e,4e,6e,8e,10e)-12-hydroxy-12-[(3e,5s)-5-(hydroxymethyl)-1-methyl-2,4-dioxopyrrolidin-3-ylidene]dodeca-2,4,6,8,10-pentaenoic acid

(2e,4e,6e,8e,10e)-12-hydroxy-12-[(3e,5s)-5-(hydroxymethyl)-1-methyl-2,4-dioxopyrrolidin-3-ylidene]dodeca-2,4,6,8,10-pentaenoic acid

C18H19NO6 (345.1212)


   

2,4-dihydroxy-6-{[(3-methylbutanoyl)oxy](phenyl)methyl}pyridine-3-carboxylic acid

2,4-dihydroxy-6-{[(3-methylbutanoyl)oxy](phenyl)methyl}pyridine-3-carboxylic acid

C18H19NO6 (345.1212)


   

10-(3-hydroxy-3-methylbutyl)-8-methoxy-4,12,14-trioxa-2-azatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1(16),2,5,7,9,11(15)-hexaen-16-ol

10-(3-hydroxy-3-methylbutyl)-8-methoxy-4,12,14-trioxa-2-azatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1(16),2,5,7,9,11(15)-hexaen-16-ol

C18H19NO6 (345.1212)